Inclusion Criteria:

          1. Subjects must meet all the following criteria to be enrolled in this study: subjects
             will voluntarily participate and sign a written informed consent.

          2. Male or female, aged at least 18 years.

          3. ECOG performance status of 0 to 2. Life expectancy of at least 12 weeks.

          4. Patients had histologically or cytologically confirmed locally advanced or metastatic
             pancreatic adenocarcinoma not amenable to curative surgery or radiotherapy.

          5. The tumour harbours one of the 2 common EGFR mutations known to be associated with
             EGFR-TKI sensitivity (Ex19del, L858R).

          6. Tumour tissue sample in a quantity sufficient to allow for central analysis of EGFR
             mutation status.

          7. Patients must be treatment-naïve for locally advanced or metastatic NSCLC and eligible
             to receive first-line treatment with gefitinib or erlotinib as selected by the
             participating centre. Prior adjuvant and neo-adjuvant therapy is permitted
             (chemotherapy, radiotherapy, investigational agents) if the disease has no progression
             during one year.

          8. At least one measurable lesion by CT or MRI. The measureable lesion should receive no
             local treatments (i.e., radiotherapy) or not used for screening biopsies (If there is
             only one target lesion that must be biopsied, baseline tumor evaluation is required at
             least 14 days after screening biopsy) and can be accurately measured at baseline with
             the longest diameter greater than 10 mm at baseline (if it is a lymph node, short
             diameter greater than 15 mm is required). If the lesions located at the regions which
             were previously treated are confirmed to progress, they can be chosen as lesion
             according to RECIST Version 1.1

          9. Females who have fertility potential before menopause should have a pregnancy test in
             the time period of 7 days prior to start of dosing, should not be breast feeding and
             must have a negative pregnancy test (blood test or urinalysis) prior to start of
             dosing; Males and females of child-bearing age must take adequate contraceptive
             measures within 3 months after signing the informed consent of the study to the last
             drug treatment.

        Exclusion Criteria:

          1. Treatment with any of the following:

               -  Prior treatment with any systemic anti-cancer therapy for locally
                  advanced/metastatic NSCLC, such as standard chemotherapy, targeted therapy,
                  biological therapy, immune therapy and for the prior adjuvant / neo-adjuvant
                  therapy listed in the inclusion criteria VII

               -  Patients received other systemic anticancer therapies for advanced/metastatic
                  non-small cell lung cancer

               -  Patients who have received intrapleural perfusion therapy should be admitted to
                  the group unless the stabilization of hydrothorax is longer than 28 days

               -  Prior treatment with an EGFR-TKI

               -  Major surgery within 4 weeks of the first dose of study drug

               -  Radiotherapy treatment to more than 30% of the bone marrow or with a wide field
                  of radiation within 4 weeks of the first dose of study drug and local
                  radiotherapy or palliative radiotherapy for bone metastasis within 14 days before
                  first drug administration

               -  Patients receiving medications or herbal supplements known to be potent
                  inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 7 days before first
                  drug administration and patients continuously taking these medications during
                  investigating period

               -  Patients taking traditional Chinese medicine and preparations whose therapeutic
                  goal is anti-tumors within 7 days before first drug administration; or
                  continuously taking these medications during investigating period

               -  Patients with any factors that increase the risk of QTc prolongation or risk of
                  Torsade ventricular tachycardia event who continuously take these medications
                  during investigating period.

               -  Before the first administration, the duration of discontinuation of other
                  clinical experimental drugs was less than 14 days

          2. Unrecovered toxic reaction due to anti-tumor therapy existed, with over 1 grade of
             CTCAE (except alopecia) or 2 grade if ever applied DDP curing related neuropathy; Bone
             marrow, liver and kidney organ function please refer to exclusion criteria 7.

          3. The tissue type is mixed type, that is, patients with lung adenocarcinoma mixed with
             lung squamous cell carcinoma.

          4. Patients with spinal cord compression, asymptomatic and stable brain metastases,
             except for those patients who have completion of the definitive therapy and steroids
             at least 28 days before investigation，or patients who received local radiotherapy for
             brain metastasis will be allowed in when the period of stabilization of brain
             metastases are at no shorter than 28 days.

          5. Patients with other malignant tumors or have a history of other malignant tumors,
             except for basal cell carcinoma of the skin, carcinoma in situ of the cervix and
             ductal carcinoma in situ of the breast.

          6. Any condition affecting the drug taking, or significantly affecting the absorption or
             the pharmacokinetic parameters, include any kind of uncontrollable nausea or vomit,
             chronic gastroenteropathy, disability in swallowing, history of gastrointestinal
             resection or surgery, uncured recurrent diarrhea, atrophic gastritis (the age of onset
             is less than 60 years old), stomach diseases, crohn's disease and ulcerative colitis
             that require long-term use of PPI antiacid drugs without cure.

          7. Patients of organ insufficiency in bone marrow, liver and kidney meet the following
             requirements (patients should receive no blood transfusion, blood product,
             hematopoietic stimulating factors, and albumin two weeks before blood sampling of
             admission )：

               -  Absolute neutrophil count < 1.5 x 109/L, Platelet count < 75 x109/L, Haemoglobin
                  < 90 g/L;

               -  Alanine aminotransferase/Aspartate aminotransferase > 2.5 times the upper limit
                  of normal (ULN) if no demonstrable liver metastases or > 5 times in the presence
                  of liver metastases;

               -  Total bilirubin > 1.5 times ULN, or >3 times ULN in the presence of definitive
                  Gilbert's syndrome (Unbound hyperbilirubinemia) or liver metastases;

               -  Creatinine >1.5 times ULN concurrent with creatinine clearance < 50 ml/min
                  (measured or calculated by Cockcroft and Gault equation);

               -  The international standardized ratio (INR) was > and 1.5, and the partial
                  activation time of prothrombin (APTT) was > 1.5 times ULN.

          8. Any condition meets the following cardiac standard:

               -  Mean resting corrected QT interval (QTc)>470 msec, obtained from 3 ECG, using the
                  screening clinic ECG machine-derived QTc value.

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG, e.g., complete left bundle branch block, third-degree heart block,
                  second-degree heart block, PR interval >250 msec

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, hypokalaemia, congenital long QT syndrome, family
                  history of long QT syndrome, or unexplained sudden death under 40 years of age in
                  first-degree relatives or any concomitant medication known to prolong the QT
                  interval.

               -  Echocardiographic examination: LVEF<50%

          9. Active infection with HBV, HCV, or HIV. All subjects will be screened for HBV, HCV, or
             Or HIV infection during the screening period:

               -  HBsAg positive, HBV DNA ≥1000cps/ml（or200IU/ml）

               -  Anti-HCV antibody was positive and HCV RNA was positive

               -  HIV antibody was positive

         10. Interstitial lung disease, drug - induced interstitial pulmonary disease, history of
             radiation pneumonia which required steroid treatment; acute or progressive pulmonary
             symptoms may occur at baseline or interstitial pulmonary disease may be identified
             that the researchers considered not suitable for trail

         11. Allergy to the study drug and/or its excipients is known or suspected

         12. Women during pregnancy or lactation

         13. Judgment by investigator that the patients should participate in the study if the
             patient is unlikely to comply with study procedure, restrictions, and requirements
             (for example, uncontrolled hypertension, uncontrolled diabetes, active bleeding
             constitution, etc.)